Repligen Corporation

NASDAQ RGEN

Download Data

Repligen Corporation Pre-Tax Margin for the quarter ending March 31, 2024: -0.85%

Repligen Corporation Pre-Tax Margin is -0.85% for the quarter ending March 31, 2024, a -104.97% change year over year. Pre-tax margin represents the proportion of a company's earnings before taxes (EBT) to its revenue. It is calculated by dividing the EBT by the revenue. This ratio indicates the profitability of the company's operations before the impact of taxes. A higher pre-tax margin suggests that the company generates a larger proportion of revenue as pre-tax profit, indicating stronger operational performance and efficiency.
  • Repligen Corporation Pre-Tax Margin for the quarter ending March 31, 2023 was 17.11%, a -41.14% change year over year.
  • Repligen Corporation Pre-Tax Margin for the quarter ending March 31, 2022 was 29.07%, a 49.82% change year over year.
  • Repligen Corporation Pre-Tax Margin for the quarter ending March 31, 2021 was 19.40%, a 20.15% change year over year.
  • Repligen Corporation Pre-Tax Margin for the quarter ending March 31, 2020 was 16.15%, a -15.07% change year over year.
NASDAQ: RGEN

Repligen Corporation

CEO Mr. Anthony J. Hunt
IPO Date March 26, 1990
Location United States
Headquarters Building 1, Waltham, MA, United States, 02453
Employees 1,783
Sector Healthcare
Industry Medical instruments & supplies
Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Similar companies

BDX

Becton Dickinson and Company

NA

NA

HOLX

Hologic Inc

NA

NA

ANGO

AngioDynamics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email